+34 93 402 04 56 info@proteodesign.es

Board and Advisors

Marc Montserrat Litchfield

Co-Founder · Member of the Board of Directors

Marc brings to ProteoDesign international business development and marketing experience in small and large biotech companies. Marc started his career as a consultant and working for Siemens VDO in Business Development, and then took a position in Almirall as Corporate Project Manager where he saw a 10x growth in revenue in the portfolio of products under his management through the integration of M&A assets, the creation of Global Brand Teams and substantial new product launches. Since 2012, he gained experience in the USA at Genentech as Senior Product Manager, at Ariosa Diagnostics as Director of Global Sales and Business Development and after Ariosa’s acquisition by Roche, as International Business Leader. Marc holds a M. of Engineering from the Universitat Politecnica de Catalunya and an MBA in Health Care Management from The Wharton School at the University of Pennsylvania.

Tom W. Muir, PhD

Co-Founder · Scientific Advisor

Tom is a renowned world-leader on protein chemistry and chemical biology. He has pioneered the field of protein ligation since his seminal invention of Expressed Protein Ligation. He was a member of The Rockefeller University Faculty, from 1996 to 2011, where he was the Richard E. Salomon Family Professor and Director of the Pels Center of Chemistry, Biochemistry and Structural Biology. In 2011, Tom joined Princeton University as the Van Zandt Williams Jr. Class of ’65 Professor of Chemistry and in 2015 became the Chair of the Department of Chemistry. He has published over 150 scientific articles and has won a number of honors for his research, including; the 2012 Jeremy Knowles Award from the Royal Society of Chemistry and a 2013 Arthur C. Cope Scholar Award from the American Chemical Society.

William B. Middlekauff

Member of the Board of Directors

Brad has broad experience in the business and legal aspects of the biotechnology industry. He is currently Senior Vice President and General Counsel of Edge Therapeutics, a publicly-traded biotechnology company. Previously, he was the inaugural Executive-in-Residence at Princeton University and has served in both business and legal capacities at biotechnology companies and their advisors for over 20 years.

Jose Antonio Mesa Cejudo

Member of the Board of Directors

Jose Antonio is the Chief Investment Officer at Caixa Capital Risc. He specializes in investment in drug development and medical devices. He currently serves on the Board of Directors at Medlumics, Stat Diagnostica, Laboratoris Sanifit, Genmedica and nLife Therapeutics. He is responsible for the analysis, negotiation and structuring of processes in life science companies. Jose A. has more than 10 years of experience in the analysis of investment opportunities and specializes in the creation and early health sector companies. His experience began in the Department of Business Development at Genzyme Corporation, a company specializing in the development and sale of drugs for orphan diseases. He later joined the Technology Portfolio team at Genoma España, a public sector foundation that promotes technology development, knowledge transfer and innovation in the biotechnology sector. Jose Antonio holds a degree in Biology (Genetics) and a Masters in Corporate Finance from the U. Complutense, Madrid (UCM), MBA and PDD from IESE.

Mireia Angulo

Member of the Board of Directors

Mireia is an Investment manager in Caixa Capital Risc, the Venture Capital arm of La Caixa. She focuses on the Life sciences sector, leading investments in companies developing therapeutics, diagnostic products and medical devices. She is currently involved in the management of various portfolio companies taking Board seats in some of them including ProteoDesign, Inbiomotion or Numat Medtech. Prior to Caixa Capital Risc, Mireia was an Investment Analyst at Healthequity, a venture capital fund focused on the healthcare sector. In addition, he held several positions in the public sector working for the technology transfer office of the University of Barcelona and the Clinical Hospital of Barcelona. Mireia holds a PhD in Genetics from University of Barcelona and earned her MBA from EADA business school.